Department of Pharmacy and Clinical Pharmacology, University of Amsterdam, Amsterdam UMC Location AMC, Amsterdam, The Netherlands; Medicines for Society Platform, Amsterdam UMC - University of Amsterdam, Amsterdam, The Netherlands.
Medicines for Society Platform, Amsterdam UMC - University of Amsterdam, Amsterdam, The Netherlands.
J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Aug 1;1243:124233. doi: 10.1016/j.jchromb.2024.124233. Epub 2024 Jul 8.
Amiodarone and mexiletine are used for ventricular arrhythmias, for which a combination therapy of both anti-arrhythmic drugs (AADs) is not uncommon. Therapeutic drug monitoring (TDM) can be beneficial for clinical guidance of therapy, especially to correctly identify adverse events. Desethylamiodarone, the active metabolite of amiodarone, accumulates over time and is associated with serious adverse events. Therefore, simultaneous TDM for amiodarone, desethylamiodarone and mexiletine is advantageous in clinical practice. The presented LC-MS/MS method was validated for selectivity, matrix effect, linearity, accuracy, precision, carry-over and stability. The method was continuously evaluated during eight months of clinical use. The method was shown to be linear within the measured range of 0.1 to 10 mg/L for each component. The matrix effect was considered negligible. No interfering responses were found for amiodarone, desethylamiodarone and the isotopic-labeled internal standards. A constant and reproducible within-run contribution of 45.3 %, originating from the system, was identified for mexiletine. The systemic contribution to the peak area of the lowest quantifiable concentration of mexiletine affected the selectivity and carry-over effect measurements. Multiple measurements showed that regression adjusted concentrations were accurate and reproducible, indicating calibration correction was applicable. Sample stability was found to be within limits for all storage conditions and freeze-thaw cycles. Furthermore, long-term method evaluation with external controls resulted in stable measurements with a percentage coefficient of variance between 1.3 % and 6.3 %. The presented practical and reliable method is applicable for clinical TDM and will allow clinical practitioners to guide drug therapy of amiodarone and mexiletine.
胺碘酮和米贝地尔用于治疗室性心律失常,通常联合应用这两种抗心律失常药物(AAD)。治疗药物监测(TDM)有助于临床指导治疗,特别是正确识别不良反应。胺碘酮的活性代谢物去乙基胺碘酮会随时间积累,与严重不良反应相关。因此,同时进行胺碘酮、去乙基胺碘酮和米贝地尔的 TDM 在临床实践中具有优势。本文介绍的 LC-MS/MS 方法经过了选择性、基质效应、线性、准确度、精密度、携带污染和稳定性验证。该方法在 8 个月的临床应用中持续进行评估。结果表明,该方法在每个成分的 0.1 至 10 mg/L 测量范围内呈线性。基质效应可忽略不计。未发现胺碘酮、去乙基胺碘酮和同位素标记内标物有干扰响应。在系统中发现米贝地尔有一个恒定且可重现的 45.3%的内源性贡献。米贝地尔最低定量浓度的峰面积选择性和携带污染效应测量受到系统内源性贡献的影响。多次测量表明,经回归校正的浓度准确且重现,表明可以进行校准校正。所有储存条件和冻融循环下的样本稳定性均在允许范围内。此外,外部对照的长期方法评估结果表明,测量值稳定,变异系数百分比在 1.3%至 6.3%之间。本文介绍的实用可靠的方法适用于临床 TDM,可帮助临床医生指导胺碘酮和米贝地尔的药物治疗。